GlassScriptPhysician profile
Huy Minh Le
NPI 1831170703
$10,470.44
in general payments reported to CMS, 2019-2025
34 companies · $2,179 in 2025
The $2,179 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,710 · 2020: $862 · 2021: $659 · 2022: $1,753 · 2023: $1,915 · 2024: $1,393 · 2025: $2,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,714 · Travel and Lodging: $525 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,713.83 |
| Travel and Lodging | $524.92 |
| Education | $247.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,962.07 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,454.63 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,389.84 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,091.43 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $928.57 | 2022-2025 | Proclaim, Freestyle Libre 3 |
| Lilly USA, LLC | $895.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $570.31 | 2023-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.96 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $310.61 | 2019-2023 | Verquvo, Belsomra |
| Sanofi-Aventis U.S. LLC | $261.55 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $207.11 | 2019 | |
| Sanofi Pasteur INC. | $121.11 | 2019-2025 | |
| Pfizer INC. | $89.27 | 2019-2024 | |
| Vbi Vaccine (Delaware) INC. | $79.92 | 2022-2023 | Prehevbrio |
| Medtronic, INC. | $77.21 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.07 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $64.35 | 2022 | |
| Eisai INC. | $57.23 | 2020 | |
| Amarin Pharma, INC. | $54.98 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $46.97 | 2019 | |
| Tactile Systems Technology INC | $39.84 | 2025 | Nimbl, Flexitouch Plus |
| Allergan, INC. | $39.08 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $38.37 | 2025 | Gemtesa |
| Exact Sciences Corporation | $36.83 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $35.02 | 2023 | Quviviq |
| Mannkind Corporation | $34.91 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $25.80 | 2019-2020 | |
| Shire North American Group INC | $18.59 | 2019 | |
| Acella Pharmaceuticals, LLC | $18.25 | 2025 | NP Thyroid 60 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.94 | 2025 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $15.18 | 2022 | |
| Seqirus USA INC | $14.48 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.45 | 2021 | |
| Amgen INC. | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huy Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.